Arch Biopartners Receives Health Canada Approval to Conduct COVID-19 Phase II Human Trial

NEXT STORY
RedHill Biopharma Receives FDA Approval for COVID-19 Clinical Study with Opaganib in the U.S.
PREV STORY
Ayala Pharmaceuticals Announces Pricing of Initial Public Offering
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Scilex Holding, a Subsidiary of Sorrento, Has Received From FDA a sNDA Approval for ZTlido® Label Expansion

author_avatar
NASDAQ Market News

Cybrexa Therapeutics Enters Cooperative Research and Development Agreement (CRADA) with U.S. National Cancer Institute to Develop CBX-12 (alphalex™- exatecan)

author_avatar
NASDAQ Market News

New Biomarker Data Supports Direct Link between VB-111’s Dual Mechanism of Action and its Clinical Effect on Overall Survival and Progression Free Survival in Recurrent Glioblastoma Multiforme Patients

TEL AVIV, Israel, Dec. 18, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), announced new ...

author_avatar
NASDAQ Market News